F-7DW8-5 7DW8-5 (Derivative of alpha-Gal-Cer)

Search for all "7DW8-5"

1 mg / €710.00
Please visit the country specific website of Acris Antibodies or contact your local Distributor to buy this product.


Product Description for 7DW8-5

Properties: (Derivative of alpha-Gal-Cer)

Properties for 7DW8-5

Product Category Natural Compounds
Quantity 1 mg
Shipping to Germany only
PDF datasheet View Datasheet
Manufacturer Funakoshi Co., Ltd.

Datasheet Extract

Add. information Shipping conditions: Dry Ice
Background There are a number of glycolipids synthesized, some of which are analogs of α-galactosyl ceramide (α-Gal-Cer), a marine sponge lipid that is the most extensively studied CD1d ligand to date. These compounds were tested for their ability to stimulate human invariant natural killer T (iNKT) cell lines, secretion of key cytokines such as IFN-g and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor. A lead compound, 7DW8-5, emerged from these studies and this glycolipid exhibits a stronger adjuvant effect than α-Gal-Cer in various HIV vaccine platforms in mice. 7DW8-5 also provides a protective adjuvant effect with a candidate malaria vaccine when tested in mice infected with malaria parasites.
While the majority of the studies performed focus on the potential of the glycolipids as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immunotherapeutic to treat cancer, infectious diseases, and autoimmune diseases.
General Readings 1) Li X, Fujio M, Imamura M, Wu D,Vasan S, Wong C-H, Ho DD, Tsuji M. 2010. Design of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl. Acad. Sci. USA. 107: 13010-13015.
2) Padte NN, Li X, Tsuji M, Vasan S. 2011. Clinical Development of a Novel CD1d-binding NKT Cell Ligand as a Vaccine Adjuvant. Clin. Immunol. 140: 142-151.
Storage Short term storage +4℃, Long term storage -20℃

Accessory Products

  • LinkedIn